This agreement reinforces our commitment to people taking
Betaseron and demonstrates our belief that when patients are adherent to their
treatment plan, there may be a greater chance for positive outcomes by reducing clinical exacerbations," said Alex Santini, Bayer's vice president of managed markets, in a statement.
Another Bayer spokesperson said the average cost of hospitalization for severe MS relapses is about $12,000.